Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Aya Hefnawy, Maya Berg, Jean-Claude Dujardin, Geraldine De Muylder

Research output: Contribution to journalA1: Web of Science-article

Abstract

New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

Original languageEnglish
JournalTrends In Parasitology
Volume33
Issue number3
Pages (from-to)162-174
Number of pages13
ISSN1471-4922
DOIs
Publication statusPublished - 2017

Keywords

  • AQUAGLYCEROPORIN AQP1 GENE
  • ABC-TRANSPORTER MRPA
  • VISCERAL LEISHMANIASIS
  • ANTIMONY-RESISTANT
  • INTRACELLULAR AMASTIGOTES
  • DONOVANI PROMASTIGOTES
  • GLUCANTIME-RESISTANT
  • TREATMENT FAILURE
  • L. DONOVANI
  • MILTEFOSINE

Fingerprint

Dive into the research topics of 'Exploiting knowledge on <em>Leishmania</em> drug resistance to support the quest for new drugs'. Together they form a unique fingerprint.

Cite this